510(k)

K063400: VARIANT II TURBO HEMOGLOBIN A1C PROGRAM, HEMOGLOBIN TESTING SYSTEM WITH CDM 4.0

FDA 510(k) · Bio-Rad Laboratories, Inc. · decided Dec 1, 2006

Key facts

510(k) number K063400
Device name VARIANT II TURBO HEMOGLOBIN A1C PROGRAM, HEMOGLOBIN TESTING SYSTEM WITH CDM 4.0
Applicant Bio-Rad Laboratories, Inc.
Product code LCP
Subsequent product codes LDM
Date received Nov 9, 2006
Decision date Dec 1, 2006
Decision Substantially equivalent (SESE)
Submission type Special
Review panel Clinical Chemistry
Medical specialty Hematology

At a glance

  • 1–9 MAUDE adverse event reports
  • 1–9 Recall events
  • None UDI device identifiers (GUDID)
  • 1–9 Predicate devices cited
  • 1–9 Later submissions citing this device
  • 100–999 510(k)s with this product code
  • Yes 510(k) summary on file
  • No 510(k) statement on file
  • Not listed On the FDA AI-enabled device list

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Reading a 510(k)

Decision
SESE means the FDA found the device substantially equivalent to its predicate, so it may be marketed in the United States.
Predicates
Each clearance cites one or more legally marketed devices; the chain of predicates shows where a technology came from.
Product code
The three-letter code sets the device type, class and regulation, and groups competing clearances.
Summary or statement
Applicants file either a 510(k) summary of the safety and effectiveness information or a statement that it is available on request.

About 510(k) premarket notifications

A 510(k) is a premarket submission made to the FDA to demonstrate that a device is substantially equivalent to a legally marketed predicate device.

Source: U.S. Food and Drug Administration (FDA), 510(k) Premarket Notification database · Source date:

Browse all 510(k) premarket notifications